Court Orders Scientific Misconduct Labels Removed From Fisher&#x27;s Work

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Roman Fabbricatore

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

Discussing Early ctDNA Detection Through MCED Blood Tests

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Tim Cortese

Highlighting Multidisciplinary Ovarian Cancer Care With Oncologists, Ophthalmologists, and Nurses

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

ONCOLOGY Staff

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

Related Content

Russ Conroy

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Roman Fabbricatore

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

Discussing Early ctDNA Detection Through MCED Blood Tests

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Tim Cortese

Highlighting Multidisciplinary Ovarian Cancer Care With Oncologists, Ophthalmologists, and Nurses

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

ONCOLOGY Staff